Aquestive Therapeutics to Participate in Two Upcoming Conferences in March
Rhea-AI Summary
Aquestive Therapeutics (NASDAQ:AQST) has announced its participation in two major investor conferences in March 2025. The company will attend:
- Leerink's Global Biopharma Conference 2025 (March 10-12), featuring a fireside chat on March 10th from 4:20-4:50pm EST
- Barclays 27th Annual Global Healthcare Conference (March 11-13), with management available for meetings on March 12th
The Leerink conference presentation will be webcast and available on the company's investor relations website under 'Events and Presentation,' with replay access for 30 days post-event. Management will be available for one-on-one meetings at both conferences.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, AQST declined 1.61%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WARREN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in March 2025 as follows:
- Leerink's Global Biopharma Conference 2025 to take place from March 10th to March 12th: fireside chat to take place on Monday, March 10th at 4:20-4:50pm EST; management will also be available for 1x1 meetings
- Barclays 27th Annual Global Healthcare Conference to take place from March 11th to March 13th; management will also be available for 1x1 meetings on March 12th
A webcast of the presentation at the Leerink's Global Biopharma Conference 2025 will be available under the “Events and Presentation” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.
About Aquestive Therapeutics, Inc.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for the treatment of possible various dermatology conditions, including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement for clinical development and approval by the U.S. Food and Drug Administration of the Company’s product candidates, including AQST-109 for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 for the treatment of possible various dermatology conditions, including alopecia areata. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Contact:
Brian Korb
astr partners
brian.korb@astrpartners.com
FAQ
When is Aquestive Therapeutics (AQST) presenting at Leerink's Global Biopharma Conference 2025?
How can investors access AQST's presentation at the Leerink Conference?
Which investor conferences will AQST attend in March 2025?
Will AQST management be available for one-on-one meetings at these conferences?
